TickerFacts.

Compare

TG Therapeutics, Inc. vs Opko Health, Inc. vs Ultragenyx Pharmaceutical Inc. vs Organogenesis Holdings Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearTG Therapeutics, Inc.
TGTX		Opko Health, Inc.
OPK		Ultragenyx Pharmaceutical Inc.
RARE		Organogenesis Holdings Inc.
ORGO
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$616.29M$606.88M$673.00M$564.17M
Revenue growth (YoY)+87.3%-14.9%+20.2%+17.0%
Gross margin83.7% (computed)33.9%n/an/a
Operating margin20.0%-19.3%-79.5%7.9%
Net margin72.6%-37.2%-85.4%6.6%
Net income$447.18M-$225.68M-$575.00M$37.03M
EPS (Diluted)$2.77-$0.30-$5.83$0.15
Operating cash flow-$24.77M-$178.54M-$466.00M-$10.31M
Free cash flow-$24.99M-$190.82M-$472.00M-$24.46M
Cash & equivalents$79.15M$364.41M$421.00M$93.68M
Total assets$1.06B$1.93B$1.53B$598.73M
Total liabilities$415.23M$663.99M$1.60B$164.81M
Shareholders' equity$648.02M$1.27B-$80.00M$300.13M
Return on year-end equity69.0%-17.8%n/a12.3%
Shares outstanding155.31Mn/a96.60M126.95M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearTG Therapeutics, Inc.Opko Health, Inc.Ultragenyx Pharmaceutical Inc.Organogenesis Holdings Inc.
Latest$616.29M
Ended 2025-12-31		$606.88M
Ended 2025-12-31		$673.00M
Ended 2025-12-31		$564.17M
Ended 2025-12-31
1 year earlier$329.00M
Ended 2024-12-31		$713.14M
Ended 2024-12-31		$560.00M
Ended 2024-12-31		$482.04M
Ended 2024-12-31
2 years earlier$233.66M
Ended 2023-12-31		$863.50M
Ended 2023-12-31		$434.00M
Ended 2023-12-31		$433.14M
Ended 2023-12-31
3 years earlier$2.79M
Ended 2022-12-31		$1.00B
Ended 2022-12-31		$363.33M
Ended 2022-12-31		$450.89M
Ended 2022-12-31
4 years earlier$6.69M
Ended 2021-12-31		$1.77B
Ended 2021-12-31		$351.41M
Ended 2021-12-31		$467.36M
Ended 2021-12-31